Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03633708 · ClinicalTrials.gov registry record · Phase 3
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
A Phase 3 study of Chronic Kidney Disease and Secondary Hyperparathyroidism, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT03633708 is a Phase 3 study of Chronic Kidney Disease and Secondary Hyperparathyroidism that is actively recruiting participants, run by Amgen. The registered enrollment target is 56 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03633708, a Phase 3 study of Chronic Kidney Disease and Secondary Hyperparathyroidism, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
Conditions Studied
Interventions
- OTHER Standard of Care
- DRUG Etelcalcetide
Study Locations (20)
National Capital Territory of Delhi
- Fortis Flt Lt Rajan Dhall Hospital - New Delhi
- All India Institute of Medical Sciences - New Delhi
- Sir Ganga Ram Hospital - New Delhi
Ohio
- Cincinnati Childrens Hospital Medical Center - Cincinnati
- Cleveland Clinic Foundation - Cleveland
Buenos Aires
- Fresenius Escobar - Belén de Escobar
- Hospital Italiano - Cuidad Autonoma de Buenos Aires
Karnataka
- Manipal Hospital - Bangalore
- KLES Dr Prabhakar Kore Hospital and Medical Research Centre - Belagavi
California
- Childrens Hospital of Los Angeles - Los Angeles
Colorado
- Childrens Hospital Colorado - Aurora
Missouri
- Childrens Mercy Hospital - Kansas City
New York
- Mount Sinai Kidney Center - B1 Renal Treatment - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-04-29 |
| Est. Completion | 2029-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03633708
The ClinicalTrials.gov registry entry for NCT03633708 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (98% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT03633708 reports 20 study locations spanning 15 distinct geographic areas - top geographies include National Capital Territory of Delhi, Ohio, Buenos Aires.
Frequently Asked Questions
What is clinical trial NCT03633708 about?
NCT03633708 is a clinical study titled "A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis". This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
What is the current status of trial NCT03633708?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2019-04-29. Estimated completion is 2029-01-31.
What conditions does trial NCT03633708 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism.
What interventions are being tested in trial NCT03633708?
The interventions under investigation include: Standard of Care (OTHER), Etelcalcetide (DRUG).
Who is sponsoring clinical trial NCT03633708?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03633708 being conducted?
This trial has 20 study locations across California, Colorado, Missouri, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
RECRUITING · Phase 3
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
ACTIVE NOT RECRUITING · Phase 3
-
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.